HSV-1 GAD Gene Delivery for Region-Specific Spasticity Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for spasticity, such as pharmacological interventions like Baclofen and surgical procedures like dorsal rhizotomy, are invasive, have significant side effects, and lack region-specific targeting, necessitating a minimally invasive, region-specific therapeutic approach.
Innovation Solution
Upregulating the GAD gene using viral vectors, such as AAV or HSV, specifically targeting sensory neurons through promoters like TRPV1 or TRPM8, to convert excitatory neurotransmitters into inhibitory neurotransmitters, thereby reducing spasticity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Baclofen is administered intrathecally using an implanted pump, then spasticity is effectively treated with reduced side effects, but post-implant complications such as pump failure, infection, and lead displacement occur
Solution Approach 1:
The patent extracts the therapeutic function from the implanted pump system by delivering the therapeutic gene (GAD) directly via viral vector injection into the spinal cord. This eliminates the need for the pump, reservoir, and leads, thereby removing the source of post-implant complications while maintaining the therapeutic benefit of intrathecal baclofen delivery through endogenous GABA production
Solution Approach 2:
The patent introduces a viral vector as an intermediary carrier to deliver the GAD gene into spinal cord cells. This intermediary enables sustained intrathecal production of GABA (the active substance) without requiring a mechanical pump, thus achieving reliable treatment delivery without the harmful complications associated with implanted devices
2Reliability
If Botulinum toxin is injected into multiple muscles, then spasticity is relieved, but the procedure requires highly trained physicians, relatively long injection times, and repetitive administration every 3-6 months
Solution Approach 1:
The patent performs preliminary action by delivering the GAD gene directly to the spinal cord, where it establishes persistent expression of GABA. This upfront genetic modification creates a long-lasting therapeutic effect that eliminates the need for repetitive injections every 3-6 months, reducing the time loss associated with frequent treatments
Solution Approach 2:
The patent changes the fundamental parameter of treatment duration from short-term (repeated injections) to long-term (sustained gene expression). By transforming the therapeutic approach from transient toxin injection to persistent genetic modification, the treatment achieves prolonged spasticity relief without requiring frequent repeat procedures
3Reliability
If neurolytic injections are administered, then spasticity is reduced, but additional necrosis of neighboring sensory nerves, skin, muscles, blood vessels, and other soft tissues occurs
Solution Approach 1:
The patent converts the harmful necrotic effect of neurolytic injections into a beneficial therapeutic effect by using viral vectors to deliver GAD gene specifically to spinal cord cells. Instead of causing tissue destruction, the therapy promotes controlled, localized production of GABA that reduces spasticity without the harmful necrosis associated with neurolytic agents
4Reliability
If dorsal rhizotomy is performed, then upper-extremity spasticity is reduced, but severe long-term adverse effects such as sensory disturbance and decrease in motor function occur
Solution Approach 1:
The patent applies local quality by targeting the GAD gene delivery specifically to the spinal cord segments responsible for spasticity while preserving other neural functions. The viral vector is injected at specific intrathecal sites to achieve localized GABA production that reduces spasticity in affected regions without causing the widespread sensory and motor deficits resulting from dorsal rhizotomy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a nonsurgical, region-specific reduction in spasticity with long-term effectiveness and minimal side effects, preserving sensory function and motor function.
Implementation Method 1
administrating to the subject a viral vector comprising a polynucleotide encoding GAD, wherein GAD is expressed, converting the excitatory neurotransmitters into inhibitory neurotransmitters
Data Source
AI summary
The present invention provides a method for treating spasticity in a subject. The method includes direct administration of a herpes simplex virus 1 (HSV-1) vector harboring a glutamic acid decarboxylase (GAD) gene (preferably. GAD67) into one or more dermatomes of the subject.